157 related articles for article (PubMed ID: 15330158)
1. Targeting chemotherapy-induced VEGF up-regulation by VEGF antisense oligonucleotides in HNSCC cell lines.
Riedel F; Götte K; Goessler U; Sadick H; Hörmann K
Anticancer Res; 2004; 24(4):2179-83. PubMed ID: 15330158
[TBL] [Abstract][Full Text] [Related]
2. Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo.
Riedel F; Götte K; Li M; Hörmann K; Grandis JR
Int J Oncol; 2003 Sep; 23(3):577-83. PubMed ID: 12888890
[TBL] [Abstract][Full Text] [Related]
3. EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration.
Riedel F; Götte K; Li M; Hörmann K; Grandis JR
Int J Oncol; 2002 Jul; 21(1):11-6. PubMed ID: 12063543
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic therapy of head and neck squamous cell carcinoma by vascular endothelial growth factor antisense therapy.
Riedel F; Götte K; Hörmann K; Grandis JR
Adv Otorhinolaryngol; 2005; 62():103-20. PubMed ID: 15608422
[TBL] [Abstract][Full Text] [Related]
5. The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer.
Bran B; Bran G; Hörmann K; Riedel F
Int J Oncol; 2009 Jan; 34(1):255-61. PubMed ID: 19082496
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Schultz JD; Mühlheim K; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
Oncol Rep; 2011 Nov; 26(5):1099-109. PubMed ID: 21805039
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/ß expression in squamous cell carcinoma of the head and neck in vitro.
Schultz JD; Rotunno S; Riedel F; Anders C; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
Int J Oncol; 2011 Apr; 38(4):1001-12. PubMed ID: 21249316
[TBL] [Abstract][Full Text] [Related]
8. Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma.
Worden B; Yang XP; Lee TL; Bagain L; Yeh NT; Cohen JG; Van Waes C; Chen Z
Cancer Res; 2005 Aug; 65(16):7071-80. PubMed ID: 16103054
[TBL] [Abstract][Full Text] [Related]
9. Signal transducers and activators of transcription 3 up-regulates vascular endothelial growth factor production and tumor angiogenesis in head and neck squamous cell carcinoma.
Masuda M; Ruan HY; Ito A; Nakashima T; Toh S; Wakasaki T; Yasumatsu R; Kutratomi Y; Komune S; Weinstein IB
Oral Oncol; 2007 Sep; 43(8):785-90. PubMed ID: 17169602
[TBL] [Abstract][Full Text] [Related]
10. Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line.
DeFatta RJ; Nathan CO; De Benedetti A
Laryngoscope; 2000 Jun; 110(6):928-33. PubMed ID: 10852506
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells.
Aukunuru JV; Ayalasomayajula SP; Kompella UB
J Pharm Pharmacol; 2003 Sep; 55(9):1199-206. PubMed ID: 14604462
[TBL] [Abstract][Full Text] [Related]
12. Tgf-beta antisense therapy increases angiogenic potential in human keratinocytes in vitro.
Riedel K; Riedel F; Goessler UR; Germann G; Sauerbier M
Arch Med Res; 2007 Jan; 38(1):45-51. PubMed ID: 17174722
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of Nafamostat mesilate on head and neck squamous cell carcinoma.
Yamashita Y; Ishiguro Y; Sano D; Kimura M; Fujita K; Yoshida T; Horiuchi C; Taguchi T; Matsuda H; Mikami Y; Tsukuda M
Auris Nasus Larynx; 2007 Dec; 34(4):487-91. PubMed ID: 17337140
[TBL] [Abstract][Full Text] [Related]
14. Abrogation of TGF-beta by antisense oligonucleotides modulates expression of VEGF and increases angiogenic potential in isolated fibroblasts from radiated skin.
Riedel K; Koellensperger E; Ryssel H; Riedel F; Goessler UR; Germann G; Kremer T
Int J Mol Med; 2008 Oct; 22(4):473-80. PubMed ID: 18813854
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Aderhold C; Umbreit C; Faber A; Sauter A; Sommer JU; Birk R; Erben P; Hofheinz RD; Stern-Straeter J; Hörmann K; Schultz JD
Anticancer Res; 2013 May; 33(5):1951-61. PubMed ID: 23645743
[TBL] [Abstract][Full Text] [Related]
16. Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A.
Detwiller KY; Fernando NT; Segal NH; Ryeom SW; D'Amore PA; Yoon SS
Cancer Res; 2005 Jul; 65(13):5881-9. PubMed ID: 15994966
[TBL] [Abstract][Full Text] [Related]
17. Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells.
Grandis JR; Chakraborty A; Zeng Q; Melhem MF; Tweardy DJ
J Cell Biochem; 1998 Apr; 69(1):55-62. PubMed ID: 9513046
[TBL] [Abstract][Full Text] [Related]
18. Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angiogenesis and immune tolerance.
Strauss L; Volland D; Kunkel M; Reichert TE
Med Sci Monit; 2005 Aug; 11(8):BR280-92. PubMed ID: 16049374
[TBL] [Abstract][Full Text] [Related]
19. IL-6 antisense-mediated growth inhibition in a head and neck squamous cell carcinoma cell line.
Bran G; Götte K; Riedel K; Hörmann K; Riedel F
In Vivo; 2011; 25(4):579-84. PubMed ID: 21708999
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous targeting of VEGF message and VEGF receptor signaling as a therapeutic anticancer approach.
Shi W; Siemann DW
Anticancer Res; 2004; 24(1):213-8. PubMed ID: 15015599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
